Abstract
Vidaza (azacitidine) in the Czech Republic to use already nearly two years as the drug of choice for patients with myelodysplastic syndrome (MDS) in a higher risk of disease (high and very high risk according IPSS.R) and in patients. with acute myeloid leukemia (AML). azacytidine synthesized in halves. 60s Czechoslovak scientists from CSAS (Piskala et al., 1964) that, for him - as the one of base analogues of DNA - tested potential cytostatic effect and its possible use of therapy malignant disease. This, however, because if identified azacytidine avoid negative effects.
This is currently changed, but despite promising effect azacytidine in hematologic malignancies is not its molecular action fully elucidated. Just published works (Dluho.ova et al., 2014) of the laboratories 1.
LF UK Prague shifts about knowledge of azacytidine step further.